en
fi
Orion Group
Menu
Menu
suomeksi
Orion Now
Other websites
Fermion
Orion Pharma Animal Health
Wehale.life
Orion countries
Orion Group
About Orion
Products and services
Partnering and licensing
Investors
Media
Corporate Governance
Contact us
Careers at Orion
Open vacancies
Working at Orion
Students
Career stories
Research
Orion R&D
Research areas
Research for patient well-being
R&D pipeline
Scientific publications
Sustainability
Policies
Management of Sustainability
Sustainability Reports
Patient organisation collaboration
Stories about responsibility
Raising the Bar
Health Professionals
Simdax.com
Dexdor.eu
Wehale.life
Orion Now
Orion Group
Orion Group
Orion's century
1910s
A superstar of Finnish chemistry
It all began with Albin and woodfern
Orion’s milestones in the 1910s
1920s
A tireless promoter of children’s health
One big family
Orion’s milestones in the 1920s
1930s
Finnishness as an advertising asset
PR in the 1930s: Welcome to the Vallila plant!
Orion’s milestones in the 1930s
1940s
A miracle drug amidst the war
Orion relocated
Orion’s milestones in the 1940s
1950s
A legendary school for laboratory assistants
Finns’ favourite ointments
Orion’s milestones in the 1950s
1960s
The man behind the research
An idyllic estate
Orion’s milestones in the 1960s
1970s
How can I help you?
International horizons: rapid tests and Finnishness
Orion’s milestones in the 1970s
1980s
New address: Orionintie 1
“For manly pain” – from drugs to brands
Orion’s milestones in the 1980s
1990s
Joining forces with a competitor
An inhaler that helps asthmatics and the atmosphere
Orion’s milestones in the 1990s
2000s
The long road to market
The last hope for a heart patient
Orion’s milestones in the 2000s
2010s
Pink light to promote girls’ rights
From a mobile phone factory to a pharmaceutical plant
Orion’s milestone in the 2010s
About Orion
Management
Board of Directors
Executive management board
Orion values
Mission and strategy
Partnering and licensing
Partnering opportunities
Alliance and Partner Management Excellence
Products and Services
Prescription drugs and self-care products
Veterinary medicine
Active Pharmaceutical Ingredients
Contract manufacturing
Investors
Orion as an investment
Market reviews
Market reviews 2021
Market reviews 2020
Market reviews 2019
Market reviews 2018
Market reviews 2017
Market reviews 2016
Market reviews 2015
Market reviews 2014
Market reviews 2013
Market reviews 2012
Market reviews 2011
Market reviews 2010
Market reviews 2009
Market reviews 2008
Market reviews 2007
CEO's review
CEO Timo Lappalainen's reviews 2021
CEO Timo Lappalainen's reviews 2020
CEO Timo Lappalainen's reviews 2019
CEO Timo Lappalainen's reviews 2018
CEO Timo Lappalainen's reviews 2017
CEO Timo Lappalainen's reviews 2016
CEO Timo Lappalainen's reviews 2015
CEO Timo Lappalainen's reviews 2014
CEO Timo Lappalainen’s reviews 2013
CEO Timo Lappalainen’s reviews 2012
CEO Timo Lappalainen's reviews 2011
CEO Timo Lappalainen's reviews 2010
CEO Timo Lappalainen’s reviews 2009
CEO Timo Lappalainen’s reviews 2008
CEO's reviews 2007
Financial Information
Key figures
Quarterly figures
Credit programmes
Outlook for 2022
Outlook for 2021
Outlook for 2020
Outlook for 2019
Outlook for 2018
Outlook for 2017
Outlook for 2016
Outlook for 2015
Outlook for 2014
Outlook for 2013
Outlook for 2012
Outlook for 2011
Outlook for 2010
Outlook for 2009
Outlook for 2008
Outlook for 2007
Outlook for 2006
Basis for outlook
Accounting policies
Calculation of key figures
Financial reviews and presentations
Capital Markets Days
Financial Statements
Share information
Share capital and shares
Share-related key figures
Treasury shares
Share price
Alternative exchanges monitor
Historical share prices
Total return calculator
Dividends
Analysts
Consensus estimates
Shareholders
Major shareholders by shares
Major shareholders by votes
Ownership structure
Flagging notifications
Insider register
Conversion of shares
Changes in shareholder's contacts
Transactions of managers
Messages to shareholders
Annual General Meetings
AGM 2022
AGM 2021
AGM 2020
AGM 2019
AGM 2018
AGM 2017
AGM 2016
AGM 2015
AGM 2014
AGM 2013
AGM 2012
AGM 2011
AGM 2010
AGM 2009
AGM 2008
AGM 2007
IR Calendar
Silent period
Archive
Investor Relations
CMD 2021
Media
Stock Exchange Releases
Press Releases
Managers' transactions
Subscribe to releases
Material Bank
Disclosure Policy
Corporate Governance
Corporate Governance
Corporate Governance Statement
AGM
Board of Directors
Activities and duties
Principles Concerning Diversity of the Board of Directors
Board members
Mikael Silvennoinen
Hilpi Rautelin
Kari Jussi Aho
Maziar Mike Doustdar
Ari Lehtoranta
Veli-Matti Mattila
Eija Ronkainen
Karen Lykke Sorensen
Board Committees
Nomination Committee
Authorisations of the Board of Directors
CEO and Executive Management Board
Activities and duties
Introductions of the Executive Management Board members
Timo Lappalainen
Satu Ahomäki
Olli Huotari
Liisa Hurme
Jari Karlson
Virve Laitinen
Outi Vaarala
Employee representative Jani Korhonen
Remuneration
Remuneration Report
Remuneration Policy
Share-based incentive plans
Risks and internal control
Strategic risks
Operational risks
Financial risks
Compliance risks
Insider administration
Audit
Articles of Association
Modern Slavery and Human Trafficking Statement
Contact us
Drug safety and product information
Locations and contact persons
Sites and offices
Pharmaceutical manufacturing
Sales offices and representative offices
Animal Health
Fermion
Contact persons
Invoicing addresses
Research
Research
Orion R&D
Orion's R&D Pipeline
Research areas
Research for patient well-being
Living with a diagnosis
Asthma
ALS
Prostate cancer
Breast cancer
Parkinson's disease
Alzheimer's disease
Drug development
Scientific publications
Clinical Research Privacy Statement
Human Data Research Privacy Statement
Orion Research Foundation
Information about the Research Foundation
The Administration of the Research Foundation
Instructions for grant applicant
Instructions for grant recipient
Orion Research Foundation's grants
Frequently asked questions
Contacts
Sustainability
Sustainability
Management of sustainability
Sustainability Agenda
Patient safety and reliable supply of medications
Environment
Responsibility for Orionees
Business ethics and transparency
Policies
Our approach to corporate responsibility
Code of Conduct
Human Resources Policy
EHS Policy
Quality Policy
Anti-Corruption Policy
Supplier requirements
Pharmaceutical R&D Ethics Policy
Bioethics and Animal Welfare
Using Human Tissues, GMO and Stem Cells
Ethics in the Clinical Research Phases
Ethics in the Marketing Phase
Sustainability Reports
Sustainability Report 2021
Previous reports
Patient organisation collaboration
Healthcare professional collaboration
Stories about responsibility
Raising the Bar
Raising the Bar
Careers at Orion
Careers at Orion
Open Vacancies
Applying for a job – questions and answers
Working in the pharmaceutical industry
Developing competence at Orion
Building personnel well-being
Career stories
Health Professionals
Employee representative Jani Korhonen
Development Manager
Jani Korhonen is the employee representative in the Executive Management Board.
Orion's century
1910s
A superstar of Finnish chemistry
It all began with Albin and woodfern
Orion’s milestones in the 1910s
1920s
A tireless promoter of children’s health
One big family
Orion’s milestones in the 1920s
1930s
Finnishness as an advertising asset
PR in the 1930s: Welcome to the Vallila plant!
Orion’s milestones in the 1930s
1940s
A miracle drug amidst the war
Orion relocated
Orion’s milestones in the 1940s
1950s
A legendary school for laboratory assistants
Finns’ favourite ointments
Orion’s milestones in the 1950s
1960s
The man behind the research
An idyllic estate
Orion’s milestones in the 1960s
1970s
How can I help you?
International horizons: rapid tests and Finnishness
Orion’s milestones in the 1970s
1980s
New address: Orionintie 1
“For manly pain” – from drugs to brands
Orion’s milestones in the 1980s
1990s
Joining forces with a competitor
An inhaler that helps asthmatics and the atmosphere
Orion’s milestones in the 1990s
2000s
The long road to market
The last hope for a heart patient
Orion’s milestones in the 2000s
2010s
Pink light to promote girls’ rights
From a mobile phone factory to a pharmaceutical plant
Orion’s milestone in the 2010s
About Orion
Management
Board of Directors
Executive management board
Orion values
Mission and strategy
Partnering and licensing
Partnering opportunities
Alliance and Partner Management Excellence
Products and Services
Prescription drugs and self-care products
Veterinary medicine
Active Pharmaceutical Ingredients
Contract manufacturing
Investors
Orion as an investment
Market reviews
Market reviews 2021
Market reviews 2020
Market reviews 2019
Market reviews 2018
Market reviews 2017
Market reviews 2016
Market reviews 2015
Market reviews 2014
Market reviews 2013
Market reviews 2012
Market reviews 2011
Market reviews 2010
Market reviews 2009
Market reviews 2008
Market reviews 2007
CEO's review
CEO Timo Lappalainen's reviews 2021
CEO Timo Lappalainen's reviews 2020
CEO Timo Lappalainen's reviews 2019
CEO Timo Lappalainen's reviews 2018
CEO Timo Lappalainen's reviews 2017
CEO Timo Lappalainen's reviews 2016
CEO Timo Lappalainen's reviews 2015
CEO Timo Lappalainen's reviews 2014
CEO Timo Lappalainen’s reviews 2013
CEO Timo Lappalainen’s reviews 2012
CEO Timo Lappalainen's reviews 2011
CEO Timo Lappalainen's reviews 2010
CEO Timo Lappalainen’s reviews 2009
CEO Timo Lappalainen’s reviews 2008
CEO's reviews 2007
Financial Information
Key figures
Quarterly figures
Credit programmes
Outlook for 2022
Outlook for 2021
Outlook for 2020
Outlook for 2019
Outlook for 2018
Outlook for 2017
Outlook for 2016
Outlook for 2015
Outlook for 2014
Outlook for 2013
Outlook for 2012
Outlook for 2011
Outlook for 2010
Outlook for 2009
Outlook for 2008
Outlook for 2007
Outlook for 2006
Basis for outlook
Accounting policies
Calculation of key figures
Financial reviews and presentations
Capital Markets Days
Financial Statements
Share information
Share capital and shares
Share-related key figures
Treasury shares
Share price
Alternative exchanges monitor
Historical share prices
Total return calculator
Dividends
Analysts
Consensus estimates
Shareholders
Major shareholders by shares
Major shareholders by votes
Ownership structure
Flagging notifications
Insider register
Conversion of shares
Changes in shareholder's contacts
Transactions of managers
Messages to shareholders
Annual General Meetings
AGM 2022
AGM 2021
AGM 2020
AGM 2019
AGM 2018
AGM 2017
AGM 2016
AGM 2015
AGM 2014
AGM 2013
AGM 2012
AGM 2011
AGM 2010
AGM 2009
AGM 2008
AGM 2007
IR Calendar
Silent period
Archive
Investor Relations
CMD 2021
Media
Stock Exchange Releases
Press Releases
Managers' transactions
Subscribe to releases
Material Bank
Disclosure Policy
Corporate Governance
Corporate Governance
Corporate Governance Statement
AGM
Board of Directors
Activities and duties
Principles Concerning Diversity of the Board of Directors
Board members
Mikael Silvennoinen
Hilpi Rautelin
Kari Jussi Aho
Maziar Mike Doustdar
Ari Lehtoranta
Veli-Matti Mattila
Eija Ronkainen
Karen Lykke Sorensen
Board Committees
Nomination Committee
Authorisations of the Board of Directors
CEO and Executive Management Board
Activities and duties
Introductions of the Executive Management Board members
Timo Lappalainen
Satu Ahomäki
Olli Huotari
Liisa Hurme
Jari Karlson
Virve Laitinen
Outi Vaarala
Employee representative Jani Korhonen
Remuneration
Remuneration Report
Remuneration Policy
Share-based incentive plans
Risks and internal control
Strategic risks
Operational risks
Financial risks
Compliance risks
Insider administration
Audit
Articles of Association
Modern Slavery and Human Trafficking Statement
Contact us
Drug safety and product information
Locations and contact persons
Sites and offices
Pharmaceutical manufacturing
Sales offices and representative offices
Animal Health
Fermion
Contact persons
Invoicing addresses
